12:00 AM
 | 
Aug 26, 2002
 |  BioCentury  |  Emerging Company Profile

Lorantis: Notching T cells

Most therapeutics to treat immune disorders focus on directly suppressing T cell activation. But for Lorantis Ltd., the world of developmental biology has uncovered what it believes to be a more natural approach to treating such diseases. The company is focusing on the human body's innate mechanism for controlling T cell regulation.

CEO Mark Bodmer said the company was born out of the "perceived need for therapeutics that block pathological responses" in disorders associated with the immune system such as allergy, asthma and transplant rejection. Few treatments attack the underlying cause of these conditions, which arise from inappropriate responses to specific antigens.

The company's technology is derived from work by researchers at Imperial College and the University of Edinburgh detailing signaling pathways involved in the regulation of the immune system."

Lorantis is dissecting the T cell regulation pathway associated with the Notch protein and its ligands. Notch was...

Read the full 732 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >